866-997-4948(US-Canada Toll Free)

BCG (Bladder Cancer) - Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Bladder Cancer

No. of Pages : 46 Pages

 


GlobalDatas pharmaceuticals report, BCG (Bladder Cancer) Analysis and Forecasts to 2020 provides BCG global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Bladder Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

 

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of BCG including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of BCG including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Global sales forecast for 2002-2020 for BCG

Reasons to buy

 

 

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

 

 

 

Table of Content

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 5
2.1 Bladder Cancer Market 5
2.2 Bladder Cancer Disease 5
2.3 GlobalData Market Forcast Report Guidance 10

3 Baldder Cancer Disease: Market Characterization 11
3.1 Bladder Cancer Disease Market 11
3.2 Bladder Cancer Disease Market Forecasts and CAGR 11
3.3 Drivers for the Bladder Cancer Disease Market 11
3.3.1 High Prevalence 12
3.3.2 High Incidence 12
3.3.3 High Survival Rate 13
3.3.4 High lifetime costs 13

4 TNM Classification of bladder cancer 14
4.1 American Urological Association 14

5 BCG 18
5.1 Introduction 18
5.2 Mechanism of Action 18
5.3 BCG Monograph 18
5.4 Treatment Regimen 18
5.5 CLINICAL STUDIES ON BCG 19
5.5.1 The SWOG trial 19
5.5.2 CONTROLLED STUDIES 21
5.5.3 10- YEAR KAPLAN-MEIER ESTIMATES 22
5.5.4 EORTC META ANALYSIS 22
5.5.5 LAMM ANALYSIS 24
5.6 BCG + Maintenance Protocol 26
5.6.1 DONALD L. LAMM RECOMMENDATIONS 26
5.6.2 MAINTENANCE BCG: 26
5.7 BCG FAILURE 28
5.7.1 CLASSIFICATION OF BCG FAILURE: 29
5.7.2 TREATMENT OPTIONS IN PATIENTS WITH BCG FAILURE: 29
5.7.3 BCG RELAPSE 31
5.7.4 BCG INTOLERANCE 31
5.8 BCG/INTERFERON COMBINATION THERAPY 33
5.8.1 MECHANISM OF ACTION 33
5.8.2 DOSE DEPENDENCY 33
5.8.3 EFFICACY 33
5.8.4 TREATMENT REGIMEN 36
5.8.5 CLINICAL RECOMMENDATION 36
5.9 Sales drivers 37
5.9.1 Bladder Cancer Market 37
5.9.2 BCG Efficacy 37
5.9.3 BCG Safety 38
5.9.4 Chemotherapy has limited advantage 38
5.10 Drug Benefit risk score 39
5.10.1 Efficacy 39
5.10.2 Safety 41
5.10.3 Compliance 41
5.10.4 Dosing Convenience 41
5.11 Sales forecast 42
5.11.1 Target patient Pool of BCG 42
5.11.2 Market Penetration 42
5.11.3 Annual Cost of Therapy 43
5.11.4 Sales Projections of BCG 43

6 Bladder Cancer Market: Appendix 44
6.1 Market Definitions 44
6.2 List of Abberiviations 44
6.3 Research Methodology 44
6.3.1 Coverage 44
6.3.2 Secondary Research 44
6.3.3 Forecasting 45
6.3.4 Number of Patients Approved to take the Drug 45
6.3.5 Net Penetration of Drug 45
6.3.6 Net Annual Dosing 45
6.3.7 Annual Cost of Therapy 46
6.3.8 Primary Research 46
6.3.9 Expert Panels 46
6.4 Contact Us 46
6.5 Disclaimer 46
6.6 Sources 46

 

List of Table


Table 1: Bladder Cancer Incidences & Mortality 6
Table 2: Bladder Cancer, Global, Market Forecast ($bn), 20022020 11
Table 3: Comparison of Percentage Progression in patients treated with BCG 22
Table 4: Efficacy of Maintenance therapy of BCG 24
Table 5: BCG Courses: Progression Rate and Metastatic Rate 31
Table 6: Drug Risk Benefit Score of BCG 39

List of Chart


Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers 5
Figure 2: Bladder Cancer Incidences & Mortality 7
Figure 4: Per capita cigarette consumption in US 8
Figure 4: Percentage of Adult population smoking in UK 8
Figure 5: Percentage share of risk factors in Developed countries 9
Figure 6: Percentage share of risk factors in Developing countries 9
Figure 7: Forecasted Global Bladder Cancer Market 11
Figure 8: All Cancer Incidence Worldwide 12
Figure 9: Bladder Cancer Incidence Worldwide 12
Figure 10: Broad Classification of Bladder Cancer 14
Figure 11: Classification of NMI Bladder Cancer 14
Figure 12: Detailed TNM Classifications 15
Figure 13: TNM staging of urothelial tract cancer as Stage I to Stage IV 16
Figure 13: Classification of NMI Bladder Cancer 16
Figure 15: BCG Monograph 19
Figure 15: SWOG Trial BCG Vs MMC 20
Figure 16: BCG Vs MMC for Low Risk Patients 20
Figure 17: Effect of Intravesical Therapy on Recurrence in Controlled Studies 22
Figure 18: Follow Up Information on Progression 23
Figure 19: Comparison of Progression rate of BCG with Maintenance 24
Figure 20: LAMM Analysis : Doxorubicin Vs BCG 25
Figure 21: Comparison of Complete Response : BCG Induction & Maintenance 26
Figure 22: Comparison of Recurrence Rate in Different Therapies 26
Figure 23: Long Term Recurrence : BCG & Chemotherapy 27
Figure 24: Long Term Recurrence : BCG & BCG+Maintenance 27
Figure 25: Results of 3 week Maintenance Therapy of BCG 28
Figure 26: Disease Free Interval for BCG Intolerant Patients 32
Figure 27: Efficacy Comparison of Agent after BCG Failure 32
Figure 28: Comparison of Recurrence rate: BCG & BCG+ Interferon 34
Figure 29: Comparison of Recurrence Rate in Different BCG Dosages 34
Figure 30: BCG+ Interferon Alfa in BCG Failures: Disease Free Survival 35
Figure 31: BCG+ Interferon Dosing Algorithm 36
Figure 32: BCG+ Interferon alfa-2b :published Clinical Trials 37
Figure 33: MMC Vs BCG for CIS 40
Figure 34: Complete Response for Different Therapies : Papillary Tumor 40
Figure 35: Complete response for CIS Tumor 41
Figure 36: Drug Model Diagram of BCG 42
Figure 37: Forecasted Sales of BCG in US,EU5,Japan ($mn) 43

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *